Pralatrexate

small molecule

Identifier: CI-DRUG-00000731
Entity page: /drug/pralatrexate ↗
Edges: 111

Neighbours: 26 cancers1 genes10 trials2 approvals
Drawn: 39 of 39 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Pralatrexate approved for …APPROVED_FOR3 of 2
→ approved for	Mature T-Cell and NK-Cell Non-Hodgkin Lymphomahematologic_malignancy	supports	FDA ORIG	Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma	1	Regulatory	openfda	graph →
→ approved for	Health Canada · CA · 2019Marketed in Canada as FOLOTYN (DIN 02481820) under ATC L01BA05 PRALATREXATE%. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.

Pralatrexate targets …TARGETS1 of 1
→ targets	DHFR	—	INHIBITOR	—	1	Curated	chembl	graph →

Pralatrexate targets …TARGETS1 of 1

→ targets

DHFR

—

INHIBITOR

—

Curated

Pralatrexate investigated for …INVESTIGATED_FOR15 of 17show all (up to 200)
→ investigated for	T-Cell Non-Hodgkin Lymphomahematologic_malignancy	unknown	4	T-Cell Non-Hodgkin Lymphoma	1	Curated	chembl	graph →
→ investigated for	Neoplasmcancer_family	unknown	4	Neoplasm	1	Curated	chembl	graph →
→ investigated for	Peripheral T-Cell Lymphoma, Not Otherwise Specifiedhematologic_malignancy	unknown	4	Peripheral T-Cell Lymphoma, Not Otherwise Specified	1	Curated	chembl	graph →
→ investigated for	Lymphomacancer_family	unknown	3	Lymphoma	1	Curated	chembl	graph →
→ investigated for	Lung Neoplasmcancer_family	unknown	2	Lung Neoplasm	1	Curated	chembl	graph →
→ investigated for	Adult T-Cell Leukemia/Lymphomahematologic_malignancy	unknown	2	Adult T-Cell Leukemia/Lymphoma	1	Curated	chembl	graph →
→ investigated for	Breast Neoplasmcancer_family	unknown	2	Breast Neoplasm	1	Curated	chembl	graph →
→ investigated for	Head and Neck Neoplasmcancer_family	unknown	2	Head and Neck Neoplasm	1	Curated	chembl	graph →
→ investigated for	Lung Non-Small Cell Carcinomasubtype	unknown	2	Lung Non-Small Cell Carcinoma	1	Curated	chembl	graph →
→ investigated for	Fallopian Tube Neoplasmsubtype	unknown	1	Fallopian Tube Neoplasm	1	Curated	chembl	graph →
→ investigated for	Ovarian Neoplasmsubtype	unknown	1	Ovarian Neoplasm	1	Curated	chembl	graph →
→ investigated for	Peritoneal Neoplasmcancer_family	unknown	1	Peritoneal Neoplasm	1	Curated	chembl	graph →
→ investigated for	Mycosis Fungoideshematologic_malignancy	unknown	1	Mycosis Fungoides	1	Curated	chembl	graph →
→ investigated for	Sezary Syndromehematologic_malignancy	unknown	1	Sezary Syndrome	1	Curated	chembl	graph →
→ investigated for	Anaplastic Large Cell Lymphomahematologic_malignancy	unknown	1	Anaplastic Large Cell Lymphoma	1	Curated	chembl	graph →

Pralatrexate investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 52show all (up to 200)
→ investigated in trials for	Peripheral T-Cell Lymphoma, Not Otherwise Specifiedhematologic_malignancy 13 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Peripheral T-Cell Lymphoma, Not Otherwise Specified	13	Observed	clinicaltrials	graph →
→ investigated in trials for	Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type 4 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Mature T-Cell and NK-Cell Non-Hodgkin Lymphomahematologic_malignancy 4 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	T-Cell Non-Hodgkin Lymphomahematologic_malignancy 4 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	T-Cell Non-Hodgkin Lymphoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Anaplastic Large Cell Lymphomahematologic_malignancy 3 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Anaplastic Large Cell Lymphoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Hepatosplenic T-Cell Lymphoma 3 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Hepatosplenic T-Cell Lymphoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Lymphomacancer_family 3 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lymphoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Primary Cutaneous T-Cell Non-Hodgkin Lymphoma 3 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Primary Cutaneous T-Cell Non-Hodgkin Lymphoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Adult Solid Neoplasm 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Adult Solid Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	B-Cell Malignant Neoplasm 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	B-Cell Malignant Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Enteropathy-Associated T-Cell Lymphoma 2 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Enteropathy-Associated T-Cell Lymphoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Esophageal Adenocarcinoma 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Esophageal Adenocarcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Esophageal Squamous Cell Carcinoma 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Esophageal Squamous Cell Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Follicular Helper T-Cell Lymphoma 2 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Follicular Helper T-Cell Lymphoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Hodgkin Lymphoma 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Hodgkin Lymphoma	2	Observed	clinicaltrials	graph →

Pralatrexate studied in …STUDIED_INderived10 of 39show all (up to 200)
→ studied in	NCT06561048Phase 3 · recruiting Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma · 39 trials list this drug (9 active)	—	—	Systemic Anaplastic Large Cell Lymphoma,T-Cell Non-Hodgkin Lymphoma,Follicular Helper T-Cell Lymphoma+2	1	Observed	clinicaltrials	graph →
→ studied in	NCT01947140Phase 1/Phase 2 · terminated Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies · 39 trials list this drug (9 active)	—	—	Lymphoma,Hodgkin Lymphoma,Multiple Myeloma+1	1	Observed	clinicaltrials	graph →
→ studied in	NCT06072131Phase 3 · recruiting To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL · 39 trials list this drug (9 active)	—	—	Peripheral T-Cell Lymphoma, Not Otherwise Specified	1	Observed	clinicaltrials	graph →
→ studied in	NCT07691450Phase 1 · not yet recruiting Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma · 39 trials list this drug (9 active)	—	—	Anaplastic Large Cell Lymphoma,Hepatosplenic T-Cell Lymphoma,Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma+2	1	Observed	clinicaltrials	graph →
→ studied in	NCT03598998Phase 1/Phase 2 · active not recruiting Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas · 39 trials list this drug (9 active)	—	—	Anaplastic Large Cell Lymphoma,Follicular Lymphoma,Hepatosplenic T-Cell Lymphoma+2	1	Observed	clinicaltrials	graph →
→ studied in	NCT07225985Phase 1/Phase 2 · recruiting Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma · 39 trials list this drug (9 active)	—	—	T-Cell Non-Hodgkin Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03240211Phase 1 · active not recruiting Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL · 39 trials list this drug (9 active)	—	—	Primary Cutaneous T-Cell Non-Hodgkin Lymphoma,Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07036133Phase 1 · recruiting Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment · 39 trials list this drug (9 active)	—	—	Hematopoietic and Lymphoid Cell Neoplasm,Solid Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT04747236Phase 2 · recruiting Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL · 39 trials list this drug (9 active)	—	—	Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01626664Phase 2 · completed KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL) · 39 trials list this drug (9 active)	—	—	Adult T-Cell Leukemia/Lymphoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths